Biotech Values

[DewDiligence]

Re: Arixtra

>Given the growing body of superior head to head trial results [of Arixtra] against Lovenox why is it having such a hard time gaining share?<

That’s a great question. Empirical evidence says Arixtra is the better drug (#msg-10569101, #msg-10588533) but docs are overwhelmingly sticking with the tried and true Lovenox.

My answer is that Arixtra lost a great deal of momentum when it was divested from SNY as a condition of the Aventis merger and ended up with GSK:
http://www.ftc.gov/opa/2004/07/sanofiaventis.htm

GSK has never given Arixtra the backing it deserves, IMO.